Vasant Jadhav — Chief Technology Officer at Alnylam Pharmaceuticals

About Vasant Jadhav

Vasant Jadhav is Chief Technology Officer at Alnylam Pharmaceuticals. Location: Cambridge, Massachusetts, United States.

Over 20 years of experience in the chemical biology research of nucleic acids spanning academic, biotech and big pharma industry for basic, diagnostic and therapeutic applications. Proven record of delivering insightful breakthroughs as an individual contributor and then growing in the role of team leader overseeing several large multi-disciplinary teams in highly collaborative and timely manner to deliver on the objectives. Optimized fully modified siRNA technology and conceived novel siRNA designs- both key assets of Sirna Therapeutics. In addition, managed collaborations with GSK and Allergan as a scientific lead in the field of respiratory and ocular diseases respectively. Initiated, established and currently overseeing biology efforts of Merck’s industry leading siRNA conjugate delivery platform. Led comprehensive efforts to engage internal and external scientific experts to unearth novel ways of enhancing cytosolic release of siRNA- the biggest barrier to fully realize potential of siRNA.

Additional experience

Senior Vice President
Alnylam Pharmaceuticals
Started July 2021

Education

Post-doctoral research, University of Colorado Boulder
Doctor of Philosophy (PhD), National Chemical Laboratory, Pune, India

Current role

Title: Chief Technology Officer
Company: Alnylam Pharmaceuticals
Location: Cambridge, Massachusetts, United States
Started: October 2023

About Alnylam Pharmaceuticals

SILENCE DISEASE. AMPLIFY LIFE.Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them.Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases.We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-25), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and Great Place to Work. We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America.See our social media community guidelines: https://bit.ly/2FcRhJy.Please note: If you wish to report an adverse event or product complaint, please email or you may call us using the following telephone numbers: for North America, (), for Europe, Fraudulent Recruitment ActivityBe aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."

Industry: Biotechnology Research
Company size: 1001-5000
Website: alnylam.com

About Vasant Jadhav

Additional experience

Senior Vice President

Education